Condition: Lupus Nephritis · Primary Membranous Nephropathy · Sponsor: Nkarta, Inc.
This is a Phase 1/2, open-label, multi-center, multi-cohort, non-randomized dose escalation and dose expansion basket study to determine the safety and tolerability of NKX019 (allogeneic CAR NK cells targeting CD19) in participants with autoimmune diseases.
This description comes directly from the study's public registry record.
Nkarta Central Contact · Only Use Email · clinicaltrials@nkartatx.com
Always discuss trial participation with your own doctor first.
| Nkarta Investigational Site | Little Rock, Arkansas, United States | Recruiting |
| Nkarta Investigational Site | Tustin, California, United States | Recruiting |
| Nkarta Investigational Site | Gainesville, Florida, United States | Recruiting |
| Nkarta Investigational Site | Miami, Florida, United States | Withdrawn |
| Nkarta Investigational Site | Plantation, Florida, United States | Recruiting |
| Nkarta Investigational Site | Tampa, Florida, United States | Recruiting |
| Nkarta Investigational Site | Atlanta, Georgia, United States | Recruiting |
| Nkarta Investigational Site | Chicago, Illinois, United States | Recruiting |
| Nkarta Investigational Site | New Orleans, Louisiana, United States | Recruiting |
| Nkarta Investigational Site | Worcester, Massachusetts, United States | Recruiting |
| Nkarta Investigational Site | Ann Arbor, Michigan, United States | Recruiting |
| Nkarta Investigational Site | Summit, New Jersey, United States | Recruiting |
+ 7 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06557265